TCGA-44-A479-01A-31R-A24H-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.440
- INTERFERON_ALPHA_RESPONSE+0.430
- INTERFERON_GAMMA_RESPONSE+0.420
- PROTEIN_SECRETION+0.330
- IL6_JAK_STAT3_SIGNALING+0.290
- COMPLEMENT+0.250
- PANCREAS_BETA_CELLS+0.190
- INFLAMMATORY_RESPONSE+0.180
- KRAS_SIGNALING_UP+0.160
- PI3K_AKT_MTOR_SIGNALING+0.110
Top 10 suppressed
- MYC_TARGETS_V2-0.440
- P53_PATHWAY-0.360
- HYPOXIA-0.350
- CHOLESTEROL_HOMEOSTASIS-0.340
- OXIDATIVE_PHOSPHORYLATION-0.330
- MYC_TARGETS_V1-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- GLYCOLYSIS-0.310
- TNFA_SIGNALING_VIA_NFKB-0.300
- ADIPOGENESIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518220 | — | D | 0.853 |
| 2 | SRR8613700 | — | D | 0.838 |
| 3 | TCGA-22-1005-01A-01R-A96U-41 | — | cohortMD2 | 0.835 |
| 4 | 3c5fe4dc-8606-4615-994f-c41861f08f5a | — | — | 0.823 |
| 5 | SRR8942978 | — | — | 0.823 |
| 6 | SRR2932840 | — | — | 0.822 |
| 7 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.819 |
| 8 | TCGA-44-3918-01A-01R-A278-07 | — | cohortMD2 | 0.814 |
| 9 | SRR12202436 | — | — | 0.810 |
| 10 | SAMN03290886 | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.180 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.090 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |